Pharma Mar (OTCMKTS:PHMMF) Shares Gap Down – Here’s What Happened

Pharma Mar (OTCMKTS:PHMMF) gapped down prior to trading on Friday . The stock had previously closed at $94.3374, but opened at $90.90. Pharma Mar shares last traded at $90.90, with a volume of 102 shares traded.

Analyst Ratings Changes

PHMMF has been the subject of a number of research analyst reports. Zacks Research raised shares of Pharma Mar to a “hold” rating in a research report on Monday, June 15th. BTIG Research began coverage on Pharma Mar in a research report on Thursday, April 23rd. They set a “buy” rating on the stock. Finally, Chardan Capital raised Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy”.

Pharma Mar Stock Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.44 and a current ratio of 3.02. The stock’s 50 day simple moving average is $96.28 and its two-hundred day simple moving average is $93.84.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.